Medical Drugs News
-
TOMI to Attend Three Leading Pharmaceutical Conferences in the First Quarter of 2023
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE ...
-
Aleksandra Rizo Appointed as CEO of Vividion Therapeutics
Vividion Therapeutics, Inc., (Vividion) a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that current President and Head of Research and Development Aleksandra Rizo, ...
By Bayer AG
-
VeriSIM Life Secures a Federal Grant to Create a Drug Combinatorial Platform Against COVID-19
VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,908 to conduct research and development (R&D) work on rapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has developed a whole-body ...
By VeriSIM Life
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Festival of Genomics: Accelerating Drug Development
Presentation entitled “Accelerating drug development through improved gene-disease association using large-scale, real-world datasets” by Robert Lumsden, PhD, Director of Business Development at the 2021 Festival of Genomics & ...
-
New partnership to advance glycoproteomics and biotherapeutics tools and research
Protein Metrics Inc., a leading provider of biopharmaceutical and proteomics analysis software, announced today a new partnership to advance glycoproteomics and biotherapeutics tools and research Macquarie University’s Analytical Glycoimmunology Group and Protein Metrics Inc. today have launched a strategic partnership scheme to further advance glycoproteomics and biotherapeutics ...
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
Meet Pluto at Bio-IT World 2022!
The Pluto team is attending our first Bio-IT World Conference & Expo in Boston May 3-5, 2022! We’re looking forward to learning about all of the impactful research the attendees are doing, and sharing how Pluto is accelerating R&D for life sciences organizations of all sizes. It’s been so exciting to see the progress over the past 6 months I’ve worked at Pluto, and I ...
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today ...
By Bayer AG
-
CD Formulation Commences Offering of Integrated Development Services for Health Care Products
As an expert in fields like drug formulation and pharmaceutical analysis, CD Formulation has made commendable achievements. More recently, it announced to commencement of offering one-stop solutions for developing healthcare formulations. Healthcare products are increasingly prevalent among the public as they can regulate the body's functions and are suitable for specific groups of people. ...
-
CD Formulation Offers 16 types of Food Ingredients as Raw Materials to Manufacture Health Care Products
Earlier this month, CD Formulation announced it has launched a wide portfolio of natural, functional, and synthetic food ingredients for both researchers and manufacturers of healthcare products. Over the past decades, numerous ingredients have performed a variety of useful functions in many types of foods. Food additives play an important role in maintaining a food supply that is flavorful, ...
-
Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
-
TOMI Expands Globally with Purchase from National Health Services (NHS) Wales
FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain. NHS Wales is a publicly funded ...
-
Alfa Chemistry Combines the Power of Computational Chemistry for Multiple Medical Applications
Computational chemistry, a branch of chemistry that applies computer simulation to assist in solving chemical problems, is a heated topic in the modern scientific community. Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on ...
-
Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
-
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
By 4D Path Inc.
-
Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids
Lipids are essential to many body functions and serve as the building blocks for living cells. Alfa Chemistry has been an ISO 9001:2015 certified supplier of nearly all forms of lipids and fatty acids and continues to broaden its product lines by adding phospholipids, modified lipids, and functionalized lipids. These lipid molecules are recently added to the already well-established collection of ...
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
-
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
-
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you